DPF3 inhibitors are a class of chemical compounds designed to specifically target and inhibit the function of DPF3 (Double PHD Fingers 3), a protein that plays a key role in chromatin remodeling and gene expression regulation. DPF3 is a member of the BAF (BRG1/BRM-associated factor) complex, which is involved in modifying chromatin structure to either promote or inhibit the transcription of specific genes. This protein contains two plant homeodomain (PHD) zinc finger motifs that allow it to recognize and bind to acetylated histones, an important post-translational modification of chromatin. By influencing chromatin accessibility, DPF3 modulates the expression of genes involved in developmental processes, including those controlling muscle differentiation and heart development. Inhibiting DPF3 provides a powerful tool for understanding its role in chromatin dynamics and transcriptional regulation.
The mechanism of DPF3 inhibitors generally involves blocking the protein's ability to bind acetylated histones, which is critical for its function in the BAF complex. These inhibitors may target the PHD finger domains or other key regions involved in chromatin recognition, preventing DPF3 from influencing chromatin remodeling and altering gene expression. Structurally, DPF3 inhibitors are often designed to mimic the acetylated histone tails or to interact with the zinc finger motifs of DPF3, thus competitively inhibiting its activity. By studying DPF3 inhibitors, researchers can explore how the regulation of chromatin accessibility affects gene transcription and how proteins like DPF3 coordinate chromatin-based control of cellular functions. This research provides valuable insights into the molecular mechanisms governing chromatin remodeling and gene expression, as well as the broader implications for cell differentiation, development, and tissue-specific gene regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Histone deacetylase inhibitor that can alter chromatin structure and gene expression. DPF3 is known to bind acetylated histones, and inhibition of deacetylation can impair DPF3's ability to interact with chromatin, thus inhibiting its function. | ||||||
I-CBP112 | 1640282-31-0 | sc-507494 | 25 mg | $400.00 | ||
CBP/p300 bromodomain inhibitor that prevents the reading of acetyl-lysine modifications on histones. Blocking these interactions can decrease the recruitment of DPF3 to chromatin, reducing its activity. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
Selective histone deacetylase inhibitor that leads to hyperacetylation of histones, potentially impairing DPF3's normal interactions with chromatin and its subsequent function. | ||||||
RGFP966 | 1357389-11-7 | sc-507300 | 5 mg | $115.00 | ||
Histone deacetylase 3 inhibitor that increases histone acetylation, potentially disrupting DPF3's interaction with chromatin and diminishing its functional activity. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
Histone acetyltransferase p300 inhibitor, which can reduce histone acetylation levels. As DPF3 binds to acetylated histones, decreased acetylation may limit DPF3's ability to bind chromatin. | ||||||
SGC-CBP30 | 1613695-14-9 | sc-473871 sc-473871A | 5 mg 10 mg | $178.00 $338.00 | ||
CBP/p300 bromodomain inhibitor that obstructs the interaction with acetylated histones. This can disrupt the chromatin binding of DPF3, which interacts with acetylated histones, and inhibit its function. | ||||||
UNC1999 | 1431612-23-5 | sc-475314 | 5 mg | $142.00 | 1 | |
EZH2 and EZH1 inhibitor which increases histone methylation. This can disrupt the epigenetic landscape that DPF3 interacts with, thereby inhibiting its chromatin-associated functions. | ||||||
PFI 3 | 1819363-80-8 | sc-507340 | 10 mg | $300.00 | ||
SMARCA bromodomain inhibitor that prevents the recognition of acetylated lysines on histones. As DPF3 has a role in chromatin remodeling, this can impede its function by altering chromatin accessibility. | ||||||
A-485 | 1889279-16-6 | sc-507493 | 5 mg | $275.00 | ||
Potent and selective catalytic inhibitor of p300/CBP histone acetyltransferase activity. By inhibiting acetylation, it can limit DPF3's ability to interact with chromatin and modulate its functional activity. | ||||||